1. UCB Bets $1.15 Billion on Neurona's Cell Therapy Pipeline in Major Biotech Acquisition
Belgian pharmaceutical giant UCB is making a massive, high-stakes bet on the future of cell therapy, agreeing to acquire U.S.-based biotech Neurona Therapeutics for up to $1.15 billion. The deal, structured with an upfront payment and significant milestone-based earnouts, signals a decisive move by the established Euro...